Neuropathy, characterized by chronic pain, numbness, and tingling sensations in the hands and feet, remains one of the most debilitating complications for patients with Type 1 diabetes. With millions of people worldwide affected by this autoimmune condition, the persistent neuropathic symptoms often degrade quality of life significantly. Traditional therapies, largely reliant on opioids and antidepressants, provide symptomatic relief but fail to address the underlying causes of nerve degeneration. Now, an innovative research initiative led by Dr. Jim Nichols at the University of Central Florida (UCF) is poised to revolutionize how diabetic neuropathy is understood and treated by exploring the critical role of insulin signaling pathways in peripheral nerves.
Type 1 diabetes arises from the immune system’s destruction of pancreatic beta cells, eliminating the body’s capacity to produce insulin, the hormone responsible for regulating blood glucose levels. Patients must undergo lifelong insulin replacement therapy to survive. Yet, even with meticulous blood sugar control, many develop peripheral neuropathy, a debilitating disorder that impairs sensation and increases the risk of potentially limb-threatening infections. Dr. Nichols’ hypothesis pivots on an unexplored mechanism: that disrupted insulin signaling in the peripheral nervous system directly contributes to the progression of neuropathic injury, independent of systemic hyperglycemia.
Prior to his appointment at UCF in 2025, Dr. Nichols honed his investigative expertise through years of research focused on the intersection of metabolic dysfunction and neural pathology. His preliminary data suggest that peripheral neurons express insulin receptors that play indispensable roles in maintaining axonal integrity and sensory function. Dysregulation in this local insulin signaling confers vulnerability to nerve damage, implicating it as a crucial pathological driver beyond the traditional focus on glucose toxicity. Supported by a $747,000 R00 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), his laboratory is rigorously deciphering these intracellular pathways to identify therapeutic targets that could halt or reverse neuropathy progression.
One of the critical challenges for patients with diabetic neuropathy is the loss of protective sensation in extremities, resulting in unnoticed injuries that subsequently become infected, often necessitating surgical interventions including amputations. Complications disproportionately affect individuals with suboptimal glycemic control, highlighting the imperative for therapies that can restore nerve function in conjunction with optimized blood glucose management. Dr. Nichols’ approach focuses on modulating insulin receptor activity and downstream signaling cascades, such as the PI3K/Akt and MAPK pathways, to enhance neuronal survival and regeneration.
“In essence, we are entering a new frontier by focusing on the peripheral insulin signaling axis,” Dr. Nichols stated. “Our goal is to uncover how altered insulin receptor function in nerves contributes to neuropathy and to develop interventions that can recalibrate or bypass dysfunctional signaling to prevent nerve degeneration.” Over the coming three years, his team will employ cutting-edge molecular biology techniques, electrophysiological assays, and in vivo diabetic models to monitor neural behavior, synaptic communication, and cell-type-specific responses within peripheral ganglia.
Unlike conventional pain management strategies that frequently involve centrally acting drugs with significant side effects and limited efficacy in diabetic neuropathy, this research promises a paradigm shift by addressing disease etiology at a cellular signaling level. Dr. Nichols envisions investigational therapeutics capable of restoring proper insulin receptor function on damaged neurons, thereby improving sensory processing and reducing neuropathic pain without the reliance on opioids or antidepressants, which often pose risks of addiction and adverse cognitive effects.
Beyond the scientific milieu, Dr. Nichols is deeply committed to mentoring the next generation of researchers drawn to biomedical innovation. He encourages students to embrace the iterative nature of scientific discovery, understanding that frequent, safe failures accelerate learning and innovation. “At UCF, we foster an environment where aspiring scientists are not deterred by setbacks but rather galvanized to refine hypotheses and experimental approaches swiftly,” he explained, underscoring the critical role of resilience in advancing translational medicine.
Graduate researcher Chisom Akaniru exemplifies this mentorship-driven ethos. Having witnessed firsthand the ravages of diabetic complications in her own family in Nigeria, she joined Dr. Nichols’ laboratory to contribute meaningfully to therapies that could alleviate neuropathic pain. “This research is deeply personal to me, given my mother’s tragic death and my father’s ongoing battle with peripheral neuropathy,” Akaniru shared. “Developing novel treatments that target the root causes could transform lives for millions of patients like them.”
Equally inspired is Hollie Hayes, a neuroscience lab manager at UCF, who transitioned from pediatric tumor research to neuropathic pain investigations. The shared goal transcends individual disease categories, centering on the broader mission to alleviate chronic, debilitating pain syndromes. “Our focus is to harness scientific advances to better the human condition and improve patient outcomes through rigorous, mechanistic research,” Hayes remarked.
Dr. Nichols’ academic journey— including a dual degree in veterinary medicine and biomedical sciences at Mississippi State University and a subsequent postdoctoral fellowship at MD Anderson Cancer Center — laid the foundation for his multidisciplinary expertise. There, he refined methodologies to investigate pathological pain mechanisms, with a special emphasis on diabetic peripheral neuropathy. His current research program at UCF continues to integrate insights from endocrinology, neuroscience, and molecular biology to deliver transformative clinical solutions.
The National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIDDK) supports this cutting-edge research with funding designed to facilitate innovative translational approaches. The awarded R00 grant, totaling nearly $750,000, will enable Dr. Nichols and his team to expand mechanistic studies, refine therapeutic targets, and move toward preclinical validation over the next three years. This work, conducted at the intersection of metabolic disease and neural function, promises to usher in new therapeutic paradigms for managing diabetic complications.
Ultimately, this research embodies a strategic pivot toward uncovering how peripheral nerve insulin signaling intricacies contribute to neuropathy pathogenesis. By disaggregating the molecular signals that dictate neuron survival and function within a diabetic context, Dr. Nichols aims to develop therapies that restore normal sensory processing and reduce patient suffering. As the burden of Type 1 diabetes and related neuropathic complications continue to grow globally, these efforts spotlight the critical need for innovative, mechanism-driven treatments.
Dr. Nichols’ exploration of insulin receptor pathways in peripheral nerve health marks a hopeful horizon in diabetes research — one where targeted molecular therapies could supplant symptom-only approaches. Success in this endeavor would represent a major advancement, offering renewed promise to millions suffering from the devastating effects of diabetic neuropathy and chronic neuropathic pain.
Subject of Research: Investigating the role of peripheral nerve insulin receptor signaling in the pathogenesis and potential treatment of diabetic peripheral neuropathy.
Article Title: Novel Insights Into Insulin Signaling Pathways Pave the Way for Next-Generation Therapies for Diabetic Neuropathy
News Publication Date: Information not provided
Web References: Information not provided
References: Information not provided
Image Credits: Photo by Eddy Duryea, UCF College of Medicine
Keywords: Type 1 diabetes, insulin signaling, diabetic neuropathy, peripheral nerves, neuropathic pain, insulin receptors, neurodegeneration, pain management, neuroscience, molecular biology, endoneurial insulin pathways
